The study sponsored by Falquetomed aims to evaluate the effectiveness and safety of the combination therapy of sibutramine and topiramate for obesity management in a real-world outpatient setting in Brazil. Given the rising prevalence of obesity and associated metabolic comorbidities, this study addresses a significant market need for affordable obesity treatments, particularly in low- and middle-income populations where newer therapies are often inaccessible due to high costs. The findings could position Falquetomed favorably in the competitive landscape of obesity treatments, especially if the combination therapy demonstrates meaningful efficacy and safety. The study's retrospective nature may limit the robustness of the data compared to prospective trials, but it could still provide valuable insights for clinical practice and inform future product development strategies.